San Jose, California (PRWEB) August 14, 2013
Follow us on LinkedIn – Worldwide influenza vaccine sales skyrocketed in the year 2009 with the introduction of vaccines to tackle the Influenza A (H1N1) pandemic virus. However, the momentum provided by the dreaded Swine Flu, ran out of steam by August 2010, with the World Health Organization (WHO) officially declaring the disease to have entered the post-pandemic stage. Nevertheless, the WHO continues to monitor outbreaks and prevalence of the H1N1 flu virus. Small outbreaks in Influenza A (H1N1)pdm09 virus were reported in certain countries of Asia, Africa, Europe, South America, as well as Central America in the post-pandemic phase. The Influenza A (H1N1)pdm09 virus is considered responsible for all the seasonal activity of (H1N1) A viruses between September 2012 and January 2013.
As a precautionary measure, WHO recommends manufacturers to include strain of A/California/7/2009 (H1N1)pdm09-like virus in the formulation of in-house seasonal influenza vaccines. Based on the WHO advisory, several governments across the globe continue to stock up on monovalent H1N1 vaccines to prevent another outbreak of the disease, besides immunizing the general population with trivalent and quadrivalent seasonal influenza vaccines, containing the analogous strain of the 2009 H1N1 virus in accordance with the availability and affordability of the vaccines in each geographic region.
The recent advancements in cell-culture and recombinant technologies are boosting the speed and efficiency of the vaccine production processes. However, the traditional egg-based production method remains the most widely used method for vaccine preparation. This method however requires l
Copyright©2012 Vocus, Inc.
All rights reserved